Skip to main content
Clinical Trials/NCT00399620
NCT00399620UnknownNot Applicable

Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis

University Hospital, Strasbourg, France2 sites in 1 country90 target enrollmentStarted: March 1, 2008Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
90
Locations
2

Study Overview

Brief Summary

Periodontitis is a chronic disease of the supporting tissue of the teeth, characterized by bleeding and inflamed gingival, resorption of alveolar bone. This disease has a significant impact of the quality of life as the teeth become progressively mobile and may fall out spontaneously if no treatment is provided. Periodontal disease has been cited as the sixth complication of diabetes mellitus.Chromogranins / secretogranins are a family of proteins present in nervous endocrine and immune cells, released with catecholamines during stress situations. Chromogranin A (CGA) is the major member of this family.The aim of this study is to determine the level of CGA and its derived peptides in the gingival crevicular fluid (GCF) of health or diabetic patients with and without periodontitis.Then, we want to determine the antimicrobial activity of these peptides.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients from 20 to 80 years old
  • A minimum of 10 teeth
  • Healthy volunteers or diabetic patients with or without periodontitis

Exclusion Criteria

  • a course of antibiotics
  • a fungicidal therapy
  • a corticotherapy
  • a hormone therapy
  • a pregnancy
  • persons under guardianship

Investigators

Sponsor
University Hospital, Strasbourg, France
Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials